<DOC>
	<DOCNO>NCT02227251</DOCNO>
	<brief_summary>Randomized two-arm , multicenter , open-label Phase 2b study 2 dos selinexor ( KPT-330 ) high patient relapsed/refractory DLBCL therapeutic option demonstrate clinical benefit .</brief_summary>
	<brief_title>Study Selinexor ( KPT-330 ) Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma ( SADAL )</brief_title>
	<detailed_description>This randomized two-arm , multicenter , open-label Phase 2b study SINE compound , selinexor . High low dos give orally patient relapsed/refractory de novo DLBCL therapeutic option demonstrate clinical benefit . Two hundred patient ( 100 per arm ) relapsed/refractory de novo DLBCL meet eligibility criteria none exclusion criterion enrol receive selinexor either disease progression intolerance occur . Patients randomize 1:1 ratio high ( 100 mg ) low ( 60 mg ) selinexor dos . Enrolled patient take fix milligram dose selinexor orally twice weekly . Patients follow disease progression and/or death .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Pathologically confirm de novo DLBCL Objective , document evidence disease progression study entry Have previously receive least 2 5 previous systemic multiagent regimen treatment DLBCL Have measurable disease At least 14 week elapse since recent systemic antiDLBCL therapy . DLBCL mucosaassociated lymphoid tissue ( MALT ) lymphoma , composite lymphoma ( HL+NHL ) DLBCL transform disease indolent NHL . Must eligible highdose therapy autologous stem cell transplantation rescue Primary mediastinal ( thymic ) large Bcell lymphoma ( PMBL ) Known central nervous system ( CNS ) lymphoma Active Hepatitis B C infection Known human immunodeficiency virus ( HIV ) infection Unable swallow tablet , patient malabsorption syndrome , GI disease GI function could interfere absorption study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diffuse large B-cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>KPT-330</keyword>
	<keyword>selinexor</keyword>
</DOC>